Skip to main content
DiagnosTear Technologies Inc. logo

DiagnosTear Technologies Inc. — Investor Relations & Filings

Ticker · DTR ISIN · CA25244H1055 LEI · 529900Y0T83PGBNF6A04 CSE Manufacturing
Open in API
Filings indexed 73 across all filing types
Latest filing 2026-03-31 Regulatory Filings
Country CA Canada
Listing CSE DTR

About DiagnosTear Technologies Inc.

https://diagnostear.com/

DiagnosTear Technologies Inc. is an ophthalmic company specializing in advanced, disruptive diagnostic solutions for the management of eye diseases. The company focuses on point-of-care diagnosis of front-of-the-eye pathologies through the analysis of tear fluid composition. Its primary technology platform, TeaRx, facilitates the multi-parameter assessment of conditions such as Dry Eye Syndrome (DES) and Severe Meibomian Gland Dysfunction (MGD). Products like the TeaRx Red Eye diagnostic device are designed for commercial readiness and large-scale manufacturing. TeaRx is positioned as a critical tool for pre- and post-operative assessment in cataract and refractive surgeries, aligning with current ophthalmic guidelines.

Recent filings

Filing Released Lang Actions
Letter from successor auditor.pdf
Regulatory Filings Classification · 1% confidence The document is a short (902-character) formal letter from an external auditor (Grant Thornton LLP) to securities commissions acknowledging and consenting to the company’s Notice of Change of Auditor, to be filed under NI 51-102. It does not present audit findings or full audit report details, nor is it an investor presentation, earnings release, or other defined category. It is a regulatory submission of a miscellaneous nature. Therefore, it best fits the fallback category “Regulatory Filings” (RNS).
2026-03-31 English
Letter from former auditor.pdf
Regulatory Filings Classification · 1% confidence The document is a formal letter from Grant Thornton Israel addressed to Canadian securities regulators under National Instrument 51-102 reviewing a Notice of Change of Auditor. It is not the full audit report itself, nor is it announcing management or board changes. It is a regulatory notice of auditor change, which does not fit into specialized categories like AR (audit report) or MANG (management change). Thus it falls into the fallback category of general regulatory filings (RNS).
2026-03-31 English
Notice.pdf
Regulatory Filings Classification · 1% confidence The document is a short notice (2,433 characters) pursuant to National Instrument 51-102 announcing a change of the Company’s external auditor from one firm to another. It does not contain the audit report itself but rather a regulatory announcement of auditor appointment/resignation. There is no full financial report, no detailed audit findings, and it is not a dividend, earnings release, management change, or proxy solicitation. Therefore, it falls under a general regulatory filing that does not fit another specific category.
2026-03-31 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a 'Form 45-106F1 Report of Exempt Distribution', which is a standard Canadian regulatory filing used to report the sale of securities that are exempt from the prospectus requirement. This document details the issuer, the distribution of securities (Class A Preferred Shares), the purchasers, and compensation paid to intermediaries. As it is a specific regulatory form filed with securities commissions, it falls under the 'Regulatory Filings' category.
2026-01-22 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing interim clinical trial results for a medical diagnostic product (TeaRx). It does not fit into financial reporting categories like 10-K or IR, nor is it a corporate governance or management change notice. Since it is a general regulatory announcement regarding company operations and product development that does not fall into the other specific categories, it is classified as a general regulatory filing.
2026-01-17 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a short press release issued by DiagnosTear Technologies Inc. in response to a request from CIRO (a regulatory body) to clarify recent market activity. It does not contain financial statements, board changes, or specific reports, but rather serves as a general regulatory announcement regarding market activity. As it does not fit into specific categories like 10-K, ER, or DIRS, it falls under the fallback category for general regulatory announcements.
2025-12-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.